NCT02955940 2025-12-17
An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib
Incyte Corporation
Phase 2 Active not recruiting
Incyte Corporation
M.D. Anderson Cancer Center
Canadian Cancer Trials Group
Ohio State University Comprehensive Cancer Center
National Cancer Institute (NCI)